



ASX

AUSTRALIAN SECURITIES EXCHANGE

# MARKET RELEASE

25 July 2011

CBIO LIMITED

SUSPENSION FROM OFFICIAL QUOTATION

The securities of CBio Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending an announcement with regard to the results of the recently completed phase IIa clinical trial in rheumatoid arthritis.

Security Code:           CBZ

Suzanna Dabski  
Senior Adviser, Listings (Sydney)

For personal use only

25 July 2011

The Manager  
Company Announcements Office  
ASX Limited  
20 Bridge St  
SYDNEY NSW 2000

Dear Sir,

**REQUEST FOR VOLUNTARY SUSPENSION**

Pursuant to Listing Rule 17.2, CBio Limited request's an immediate voluntary suspension of the company's securities ("ASX: CBZ") pending the release of a material announcement concerning the recently completed phase IIa clinical trial in rheumatoid arthritis.

The Company entered into a trading halt on 21 July, however since that time additional data from the trial has been received, and this data requires further analysis. The period of voluntary suspension will allow that analysis to be completed and then reviewed by the Board prior to the appropriate disclosure being made to the market.

The Company expects to make this announcement before the opening of trade on Monday 8 August.

The Company is not aware of any reason why the voluntary suspension should not be granted.

For and on behalf of the Board of CBio Limited



**BEN GRAHAM**  
Company Secretary

COMPANY & INVESTOR RELATIONS  
Ben Graham  
Company Secretary  
CBio Limited  
T: +61 7 3841 4844  
ben.graham@cbio.com.au

MEDIA LIAISON  
Melanie Farris  
Manager, Corporate Projects  
CBio Limited  
T: +61 449 148 448  
melanie.farris@cbio.com.au

For personal use only

### **About CBio**

CBio is an Australian ASX listed company established in 2000. CBio's lead product XToll® is a potential new-generation drug therapy which could provide safer and more effective treatment of autoimmune diseases such as rheumatoid arthritis. It is currently being trialled in phase II clinical trials in patients with rheumatoid arthritis (RA). Global sales of RA therapies exceeded US\$17 billion in 2008.

Novo Nordisk A/S (Copenhagen: NOVO-B.CO; NYSE: NVO), a top 20 global pharmaceutical company and world-leader in diabetes care, has an exclusive option to enter into negotiations for a licence agreement for the intellectual property rights relating to XToll®.

CBio's Board includes internationally experienced drug developers including Dr Göran Ando, Vice-Chairman Novo Nordisk A/S (formerly president of R&D at Pharmacia/Pfizer and R&D director of Glaxo Group, UK); Dr Thomas Lönngrén (former Executive Director of the European Medicines Agency), Dr Terje Kalland (retired Vice President Biopharmaceuticals Research Unit- Novo Nordisk), Dr Peter Corr, Founder and co-General Partner of Celtic Therapeutics (formerly Senior Vice-President for Science and Technology at Pfizer and Chairman of the Board of Governors, New York Academy of Sciences); and Professor John Funder, AO, Professor of Medicine at Monash University, Senior Fellow at Prince Henry's Institute of Medical Research (formerly Director of the Baker Institute, 1990-2001).

### **About Rheumatoid Arthritis**

Rheumatoid Arthritis is a chronic autoimmune disease, mainly characterised by inflammation of the lining of the joints. It can lead to long-term joint damage, resulting in chronic pain, loss of function and disability. The effects of RA are systemic, which means it can affect other organs in the body, and cardiovascular dysfunction in addition to RA is common. RA symptoms can make even the simplest activities – such as opening a jar or taking a walk – difficult to manage. RA has a worldwide distribution with a prevalence of 1 to 2% – which currently equates to approximately 100 million people. Prevalence increases with age, approaching 5% in women over age 55. RA is two to three times more common in women than in men and generally occurs between the ages of 40 and 60, but it can also affect young children and older adults. Currently, there is no cure.

For personal use only